Top 10 Pharmaceutical Stocks with Highest Upside: ARYX, DARA, PRAN, XOMAD, CBRX, EPCT, PIP, MRNA, CYTR, STEM (Oct 04, 2010)

"Strong Buy" Rated U.S.-Listed Chinese Stocks (March 13, 2012)

Below are the top 10 Pharmaceutical stocks with highest upside potential, UPDATED TODAY before 4:30 AM ET, based on the difference between current price and Wall Street analysts' average target price.


ARYx Therapeutics, Inc. (NASDAQ:ARYX) has the 1st highest upside potential in this segment of the market. Its upside is 984.7%. Its consensus target price is $4.25 based on the average of all estimates. DARA BioSciences, Inc. (NASDAQ:DARA) has the 2nd highest upside potential in this segment of the market. Its upside is 578.0%. Its consensus target price is $16.00 based on the average of all estimates. Prana Biotechnology Limited (ADR) (NASDAQ:PRAN) has the 3rd highest upside potential in this segment of the market. Its upside is 572.3%. Its consensus target price is $8.00 based on the average of all estimates. XOMA Limited (NASDAQ:XOMAD) has the 4th highest upside potential in this segment of the market. Its upside is 429.3%. Its consensus target price is $16.25 based on the average of all estimates. Columbia Laboratories Inc. (NASDAQ:CBRX) has the 5th highest upside potential in this segment of the market. Its upside is 260.4%. Its consensus target price is $4.00 based on the average of all estimates.

EpiCept Corporation (NASDAQ:EPCT) has the 6th highest upside potential in this segment of the market. Its upside is 233.3%. Its consensus target price is $2.00 based on the average of all estimates. PharmAthene, Inc. (AMEX:PIP) has the 7th highest upside potential in this segment of the market. Its upside is 226.8%. Its consensus target price is $5.00 based on the average of all estimates. Marina Biotech, Inc. (NASDAQ:MRNA) has the 8th highest upside potential in this segment of the market. Its upside is 221.1%. Its consensus target price is $7.67 based on the average of all estimates. CytRx Corporation (NASDAQ:CYTR) has the 9th highest upside potential in this segment of the market. Its upside is 220.5%. Its consensus target price is $2.50 based on the average of all estimates. StemCells, Inc. (NASDAQ:STEM) has the 10th highest upside potential in this segment of the market. Its upside is 220.2%. Its consensus target price is $2.60 based on the average of all estimates.

Subscribe to Our Free Newsletter: